135 related articles for article (PubMed ID: 10377280)
1. The PML nuclear bodies: actors or extras?
Seeler JS; Dejean A
Curr Opin Genet Dev; 1999 Jun; 9(3):362-7. PubMed ID: 10377280
[TBL] [Abstract][Full Text] [Related]
2. Role of SUMO-1-modified PML in nuclear body formation.
Zhong S; Müller S; Ronchetti S; Freemont PS; Dejean A; Pandolfi PP
Blood; 2000 May; 95(9):2748-52. PubMed ID: 10779416
[TBL] [Abstract][Full Text] [Related]
3. The PML nuclear compartment and cancer.
Doucas V; Evans RM
Biochim Biophys Acta; 1996 Dec; 1288(3):M25-9. PubMed ID: 9011178
[No Abstract] [Full Text] [Related]
4. Regulation of Pax3 transcriptional activity by SUMO-1-modified PML.
Lehembre F; Müller S; Pandolfi PP; Dejean A
Oncogene; 2001 Jan; 20(1):1-9. PubMed ID: 11244500
[TBL] [Abstract][Full Text] [Related]
5. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins.
Chelbi-Alix MK; de Thé H
Oncogene; 1999 Jan; 18(4):935-41. PubMed ID: 10023669
[TBL] [Abstract][Full Text] [Related]
6. [Research advances on function of promyelocytic leukemia (PML) protein].
He PC; Zhang M; Wang F
Ai Zheng; 2003 Dec; 22(12):1359-62. PubMed ID: 14693070
[TBL] [Abstract][Full Text] [Related]
7. Regulation of p53 activity in nuclear bodies by a specific PML isoform.
Fogal V; Gostissa M; Sandy P; Zacchi P; Sternsdorf T; Jensen K; Pandolfi PP; Will H; Schneider C; Del Sal G
EMBO J; 2000 Nov; 19(22):6185-95. PubMed ID: 11080164
[TBL] [Abstract][Full Text] [Related]
8. Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus.
Muratani M; Gerlich D; Janicki SM; Gebhard M; Eils R; Spector DL
Nat Cell Biol; 2002 Feb; 4(2):106-10. PubMed ID: 11753375
[TBL] [Abstract][Full Text] [Related]
9. [Progress in researches on the function of PML gene].
Zhou L; Chen G; Shen Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Apr; 17(2):132-5. PubMed ID: 10751540
[TBL] [Abstract][Full Text] [Related]
10. PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL.
di Masi A; Cilli D; Berardinelli F; Talarico A; Pallavicini I; Pennisi R; Leone S; Antoccia A; Noguera NI; Lo-Coco F; Ascenzi P; Minucci S; Nervi C
Cell Death Dis; 2016 Jul; 7(7):e2308. PubMed ID: 27468685
[TBL] [Abstract][Full Text] [Related]
11. PML/RARalpha, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells.
Fu S; Consoli U; Hanania EG; Zu Z; Claxton DF; Andreeff M; Deisseroth AB
Clin Cancer Res; 1995 Jun; 1(6):583-90. PubMed ID: 9816019
[TBL] [Abstract][Full Text] [Related]
12. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
Ahn MJ; Nason-Burchenal K; Moasser MM; Dmitrovsky E
Oncogene; 1995 Jun; 10(12):2307-14. PubMed ID: 7784078
[TBL] [Abstract][Full Text] [Related]
13. The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic.
Andre C; Guillemin MC; Zhu J; Koken MH; Quignon F; Herve L; Chelbi-Alix MK; Dhumeaux D; Wang ZY; Degos L; Chen Z; de The H
Exp Cell Res; 1996 Dec; 229(2):253-60. PubMed ID: 8986606
[TBL] [Abstract][Full Text] [Related]
14. cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha.
Duprez E; Lillehaug JR; Naoe T; Lanotte M
Oncogene; 1996 Jun; 12(11):2451-9. PubMed ID: 8649787
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of component exchange at PML nuclear bodies.
Weidtkamp-Peters S; Lenser T; Negorev D; Gerstner N; Hofmann TG; Schwanitz G; Hoischen C; Maul G; Dittrich P; Hemmerich P
J Cell Sci; 2008 Aug; 121(Pt 16):2731-43. PubMed ID: 18664490
[TBL] [Abstract][Full Text] [Related]
16. The functional roles of PML nuclear bodies in genome maintenance.
Chang HR; Munkhjargal A; Kim MJ; Park SY; Jung E; Ryu JH; Yang Y; Lim JS; Kim Y
Mutat Res; 2018 May; 809():99-107. PubMed ID: 28521962
[TBL] [Abstract][Full Text] [Related]
17. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1.
Sternsdorf T; Jensen K; Will H
J Cell Biol; 1997 Dec; 139(7):1621-34. PubMed ID: 9412458
[TBL] [Abstract][Full Text] [Related]
18. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins.
Zhong S; Delva L; Rachez C; Cenciarelli C; Gandini D; Zhang H; Kalantry S; Freedman LP; Pandolfi PP
Nat Genet; 1999 Nov; 23(3):287-95. PubMed ID: 10610177
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia.
Grimwade D; Solomon E
Curr Top Microbiol Immunol; 1997; 220():81-112. PubMed ID: 9103677
[TBL] [Abstract][Full Text] [Related]
20. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
